Subsense BCI - Bryant McGill

# Subsense BCI **Entity class:** Technology, method, or technical system **Aliases:** Subsense; Subsense Inc.; @subsenseBCI **Domain:** Brain-Computer Interfaces / Neurotechnology / Nanotechnology / Human-Machine Convergence **Doc Type:** Institution and Technology Node **Maturity:** Developed **Epistemic State:** Company, personnel, and announced roadmap documented; platform remains preclinical ## Definition **Subsense Inc. is a Palo Alto neurotechnology company developing NanoBCI, a proposed non-surgical, nanoparticle-mediated brain-computer-interface platform.** The company describes a modular architecture combining functional nanoparticles with wearable wireless hardware to read and stimulate neural activity. Subsense's public roadmap places the work in preclinical development. Its site projects clinical pilots for 2027–2029, a possible clinical product in 2029–2031, and consumer BCI applications after 2031. Subsense also states that its products are not authorized, cleared, or approved by the FDA for U.S. marketing and that performance claims have not been evaluated by the FDA. ## Nanotechnology and neuropharmacology first Subsense should be analyzed first as a **nanotechnology, neuropharmacology, and molecular-interface problem**, and only secondarily as a conventional BCI company. Its strategic discontinuity is the movement of part of the interface away from permanently implanted electronics and toward administered functional material inside the biological substrate: - intranasal administration; - biodistribution and blood-brain-barrier transit; - targeted localization; - plasmonic nanoparticles for optical neural readout; - magnetoelectric nanoparticles for externally driven local neuromodulation; and - wearable hardware as the external energizing, interrogating, and computational layer. That architecture must eventually be evaluated with device and pharmacological vocabulary together: dose, delivery route, tissue distribution, targeting, residence time, repeat dosing, clearance or degradation, toxicity, immunogenicity, tissue accumulation, reversibility, and persistence. Subsense's current materials describe goals and preliminary laboratory work; they do not settle these translational questions. ## N3, MOANA, and Merge genealogy [[wiki/DARPA N3|DARPA N3]] and Rice's [[wiki/MOANA|MOANA]] project are publicly documented ancestors of the broader design pattern: nonsurgical or minutely invasive neural access, temporary nanotransducers or biologically delivered components, external optical/acoustic/electromagnetic transceivers, and bidirectional read-write objectives. This is an architectural genealogy, not proof that Subsense received MOANA technology or descends organizationally from the Rice program. [[wiki/Merge Labs|Merge Labs]] belongs on the same longitudinal route through its biology-device-AI approach and announced ultrasound-on-chip development platform. The three implementations remain technically distinct. ## Kurzweil convergence The connection to [[wiki/Ray Kurzweil|Ray Kurzweil]] is now institutional rather than merely thematic: - Subsense lists **John-Clark Levin**, Research Lead at Kurzweil Technologies, as a product advisor. - On September 9, 2026, Subsense announced that **Ray Kurzweil had joined as Product and Vision Advisor**, advising on long-range product and technology development and the convergence of AI with neural interfaces. The appointment documents advisory participation and a shared horizon of AI-neural convergence. It is not experimental validation of NanoBCI or evidence that the proposed system has succeeded in humans. ## Lorimer network route Bryant first identified `@subsenseBCI` and `@LorimerVentures` as an unusual X-network adjacency. The reviewed public record does not establish a direct [[wiki/Lorimer Ventures|Lorimer Ventures]] investment in Subsense. A more concrete one-degree professional path nevertheless exists: **Lorimer Ventures → Formic ← Lux Capital / Shahin Farshchi → Subsense Annual Forum.** Formic's 2022 Series A announcement identifies Lorimer Ventures as a participant, Lux Capital as lead investor, and Shahin Farshchi as a new board member. Farshchi later participated in Subsense's September 2026 forum. His relevance is unusually specific: he co-authored a 2006 IEEE paper describing a wireless neural interface. This is a documented network bridge, not evidence of a hidden cap-table relationship or coordinated X-account activity. ## Blackrock Neurotech bridges The relation to [[wiki/Blackrock Neurotech|Blackrock Neurotech]] is stronger than ordinary industry adjacency and runs through at least two independent functions: - **Lindsey Jardine**, a former Blackrock Vice President of Clinical and Regulatory, is Subsense's Regulatory Advisor and is described by Subsense as leading its FDA TAP Pilot and Breakthrough-neurotechnology strategies. - **Sergey Stavisky**, a Subsense Scientific Advisor, conducts human neural-decoding research using Blackrock NeuroPort hardware and has BCI intellectual property licensed to Blackrock. Jardine carries clinical-regulatory experience; Stavisky carries scientific, signal, hardware, and IP experience. Together they place Subsense inside a shared developmental ecology with the mature invasive benchmark it seeks to approach without conventional surgery. They do not establish a Blackrock investment in Subsense or validate Subsense's nanoparticle platform. Upstream, [[wiki/Tether Evo|Tether Evo]] is Blackrock's majority owner following a $200 million investment in 2024 and is developing local-first neural-speech decoding through BrainWhisperer and QVAC. The conservative route is **Tether Evo → Blackrock Neurotech → Jardine / Stavisky → Subsense**, not Tether → Subsense. ## Continuity significance Subsense occupies the proposed interface between machine intelligence as an external computational service and machine intelligence as part of the addressable human cognitive environment. If systems of this class eventually become safe, bidirectional, and high-bandwidth, they could become infrastructure for [[wiki/Human-Machine Symbiosis|Human-Machine Symbiosis]], memory augmentation, synthetic sensory channels, and [[wiki/Consciousness Continuity Infrastructure|Consciousness Continuity Infrastructure]]. Those are prospective implications, not present capabilities. ## Routes [[wiki/Ray Kurzweil|Ray Kurzweil]] · [[wiki/Lorimer Ventures|Lorimer Ventures]] · [[wiki/Blackrock Neurotech|Blackrock Neurotech]] · [[wiki/Tether Evo|Tether Evo]] · [[wiki/DARPA N3|DARPA N3]] · [[wiki/MOANA|MOANA]] · [[wiki/Merge Labs|Merge Labs]] · [[wiki/Neural Interfaces and Continuity Architecture|Neural Interfaces and Continuity Architecture]] · [[wiki/Human-Machine Symbiosis|Human-Machine Symbiosis]] · [[wiki/Consciousness Continuity Infrastructure|Consciousness Continuity Infrastructure]] · [[wiki/Machine Succession|Machine Succession]] · [[wiki/Cicada 3301|Cicada 3301]] ## Sources / Provenance - Subsense, [NanoBCI technology and development milestones](https://subsense-bci.com/technology/). - Subsense, [Team, collaborators, and advisors](https://subsense-bci.com/about-us/). - Subsense, [News and press: Ray Kurzweil joins Subsense as Product and Vision Advisor](https://subsense-bci.com/news/), September 9, 2026. - Formic, [Formic's Series A Raise](https://formic.co/resources/articles/formics-series-a-raise), January 18, 2022. - PubMed, [A TinyOS-enabled MICA2-based wireless neural interface](https://pubmed.ncbi.nlm.nih.gov/16830946/), IEEE Transactions on Biomedical Engineering, July 2006. - DARPA, [Six Paths to the Nonsurgical Future of Brain-Machine Interfaces](https://www.darpa.mil/news/2019/nonsurgical-brain-machine-interfaces), May 20, 2019. - Rice University, [Feds fund creation of headset for high-speed brain link](https://news.rice.edu/news/2019/feds-fund-creation-headset-high-speed-brain-link), May 20, 2019. - Blackrock Neurotech, [Tether invested $200M in Blackrock Neurotech](https://blackrockneurotech.com/insights/tether-invested-200m-in-blackrock-neurotech-accelerating-development-and-commercialization-of-implantable-bci-technology/), April 29, 2024. - Bryant-supplied network-convergence and molecular-interface research memoranda, September 7, 2026 — source of the original X-adjacency observation, multi-path topology, and longitudinal framing. ## Relationships  This entry is routed through [[collections/Neurotech|Neurotech]] and [[collections/Consciousness Continuity|Consciousness Continuity]]. Its source context is developed in [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]], [[articles/The Architecture of Continuity and Emerging Neuroinformatics Standards|The Architecture of Continuity and Emerging Neuroinformatics Standards]], [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]], and [[articles/The Organic-Synthetic Brain Atlas|The Organic-Synthetic Brain Atlas]]. Status-qualified source edges are preserved in the terminal Research Edges section. ### Additional Documented Relationships - The technical comparison identifies a convergence: [[wiki/Merge Labs|Merge Labs]] provides a technical overlay for **Subsense BCI**. Both seek high-bandwidth. less-invasive molecular/material-mediated interfaces. transduction differs: ultrasound/biology emphasis versus plasmonic+MENP nanoparticle bioplatform. - The technical comparison identifies a convergence: **Subsense BCI** provides a technical overlay for [[wiki/MOANA|MOANA]]. Both combine optical readout concepts with magnetic nanoparticle-mediated intervention. no public corporate/IP lineage established here. - The source corpus interprets the relationship this way: [[wiki/Motif Neurotech|Motif Neurotech]] is associated with **Subsense BCI**. Both exploit magnetoelectric physics in neurotechnology. but Motif uses millimeter-scale implanted wireless power/stimulation while Subsense uses nanoparticle-scale distributed transduction. - [[wiki/Blackrock Neurotech|Blackrock Neurotech]] is associated with **Subsense BCI**. Lindsey Jardine formerly led clinical/regulatory work at Blackrock and now advises Subsense. - [[wiki/Science Corporation|Science Corporation]] is associated with **Subsense BCI**. Angel Bravo moved from Science Corp experience into Subsense hardware leadership. - **Subsense BCI** serves or served as an advisor to [[wiki/Naomi J. Halas|Naomi J. Halas]]. Plasmonics/nanophotonics bridge.  ## Related Work in the Corpus  - In [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]], **IX. The escape from the electrode** provides the narrative context for **Subsense BCI**: The magnetoelectric nanoparticle lineage — running through Sakhrat Khizroev's work and Ping Liang's Cellular Nanomed — supplies the distributed molecular transduction branch.  ## Research Edges  #### Master relationship graph patch — 2026-09-10 **Resolved aliases:** `Subsense` **Collection:** [[collections/Neurotech|Neurotech]] **Relationship source:** [[research/Neurotechnology Ecosystem Relationship Graph - 2026-09-10|Neurotechnology Ecosystem Relationship Graph — 2026-09-10]] **Related source articles:** [[articles/The Architecture of Continuity and Emerging Neuroinformatics Standards|The Architecture of Continuity and Emerging Neuroinformatics Standards]] · [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] · [[articles/The Organic-Synthetic Brain Atlas|The Organic-Synthetic Brain Atlas]] #### Outgoing typed edges - **Edge 7 — `co_founded_by` → [[wiki/Tetiana Aleksandrova|Tetiana Aleksandrova]]** — **VERIFIED**; evidence `SUB_ABOUT`. Current official team page. - **Edge 8 — `co_founded_by` → [[wiki/Scott Meek|Scott Meek]]** — **VERIFIED**; evidence `SUB_ABOUT`. Current official team page identifies Head of R&D & Co-Founder. - **Edge 9 — `co_founded_by` → [[wiki/Artem Sokolov|Artem Sokolov]]** — **VERIFIED_SECONDARY**; evidence `GOLDEN_FALCON`. Public founder/funding materials identify Sokolov as co-founder; current Subsense team page foregrounds other founders, so preserve source/date context. - **Edge 10 — `funded_by` → [[wiki/Golden Falcon Capital|Golden Falcon Capital]]** — **VERIFIED**; evidence `SUB_HOME`, `AXIOS_SUB`, `GOLDEN_FALCON`. $17M seed plus $10M extension; Subsense reports $27M total seed financing. - **Edge 12 — `research_partner` → [[wiki/University of California, Santa Cruz|University of California, Santa Cruz]]** — **VERIFIED_SECONDARY**; evidence `SUB_HOME`. Partnership stated in company/founder funding materials; connect to NanoEngineering Lab through Ali Yanik. - **Edge 13 — `research_partner` → [[wiki/ETH Zürich|ETH Zürich]]** — **VERIFIED_SECONDARY**; evidence `SUB_HOME`. Partnership stated in company/founder funding materials. - **Edge 14 — `platform_contains` → [[wiki/Plasmonic Nanoparticle|plasmonic nanoparticles]]** — **VERIFIED**; evidence `SUB_TECH`. Optical neural readout via differential NIR scattering in local electric fields. - **Edge 15 — `platform_contains` → [[wiki/Magnetoelectric Nanoparticle|magnetoelectric nanoparticles (MENPs)]]** — **VERIFIED**; evidence `SUB_TECH`. Targeted neuromodulation by conversion of applied magnetic fields to local electric effects. - **Edge 16 — `platform_contains` → [[wiki/NanoBCI|wearable wireless device]]** — **VERIFIED**; evidence `SUB_TECH`. External control/readout layer of modular bioplatform. - **Edge 17 — `uses_delivery_route` → intranasal nanoparticle administration** — **VERIFIED**; evidence `SUB_HOME`. Company describes non-surgical brain access through intranasal administration. - **Edge 18 — `uses_localization_strategy` → controlled nanoparticle navigation to brain regions** — **VERIFIED**; evidence `SUB_HOME`. Company describes targeted localization. - **Edge 19 — `uses_readout_modality` → [[wiki/Near-Infrared Neural Sensing|near-infrared optical scattering]]** — **VERIFIED**; evidence `SUB_TECH`. Plasmonic neural readout. - **Edge 20 — `uses_write_modality` → [[wiki/Magnetoelectric Nanoparticle|magnetoelectric neuromodulation]]** — **VERIFIED**; evidence `SUB_TECH`. MENP stimulation. - **Edge 21 — `initial_indication` → [[wiki/Parkinson's Disease|Parkinson’s disease]]** — **VERIFIED**; evidence `SUB_HOME`. Company medical-impact horizon. - **Edge 22 — `initial_indication` → [[wiki/Drug-Resistant Epilepsy|drug-resistant epilepsy]]** — **VERIFIED**; evidence `SUB_HOME`. Company medical-impact horizon. - **Edge 23 — `regulatory_status` → early FDA engagement; no marketing authorization** — **VERIFIED**; evidence `SUB_HOME`, `SUB_NEWS`. Do not imply FDA clearance or approval. - **Edge 24 — `advisor` → [[wiki/Ray Kurzweil|Ray Kurzweil]]** — **VERIFIED**; evidence `SUB_ABOUT`, `SUB_NEWS`. Product/vision or scientific-advisor role is current as of 2026-09-09. - **Edge 26 — `advisor` → [[wiki/Naomi J. Halas|Naomi J. Halas]]** — **VERIFIED**; evidence `SUB_ABOUT`, `SUB_ROUNDTABLE`. Plasmonics/nanophotonics bridge. - **Edge 28 — `collaborator` → [[wiki/Ali Yanik|Ali A. Yanik]]** — **VERIFIED**; evidence `SUB_ABOUT`. Director of UCSC NanoEngineering Lab. - **Edge 30 — `advisor` → [[wiki/Sergey Stavisky|Sergey Stavisky]]** — **VERIFIED**; evidence `SUB_ABOUT`. Speech/language neuroprosthetics bridge. - **Edge 32 — `advisor` → [[wiki/David Eagleman|David Eagleman]]** — **VERIFIED**; evidence `SUB_ABOUT`. Sensory substitution / neuroplasticity bridge. - **Edge 35 — `regulatory_advisor` → [[wiki/Lindsey Jardine|Lindsey Jardine]]** — **VERIFIED**; evidence `SUB_ABOUT`. Regulatory transfer from implanted BCI sector. - **Edge 37 — `advisor` → [[wiki/Ajeet Kaushik|Ajeet Kaushik]]** — **VERIFIED**; evidence `SUB_ABOUT`. NanoBioTech and drug-delivery/theranostics adjacency. - **Edge 38 — `advisor` → [[wiki/John-Clark Levin|John-Clark Levin]]** — **VERIFIED**; evidence `SUB_ABOUT`, `SUB_ROUNDTABLE`. AI/product strategy bridge to Kurzweil Technologies. - **Edge 40 — `roundtable_participant` → [[wiki/Jennifer Dionne|Jennifer Dionne]]** — **VERIFIED**; evidence `SUB_ROUNDTABLE`. Stanford nanophotonics; nanoscale biological observation/control. - **Edge 41 — `roundtable_participant` → [[wiki/Andrew Jackson|Andrew Jackson]]** — **VERIFIED**; evidence `SUB_ROUNDTABLE`. Newcastle neural interfaces/brain-machine systems. - **Edge 42 — `roundtable_participant` → [[wiki/Corey Keller|Corey Keller]]** — **VERIFIED**; evidence `SUB_ROUNDTABLE`. Stanford neurostimulation and circuit mapping. - **Edge 43 — `employs` → [[wiki/Ranya Belmaachi|Ranya Belmaachi]]** — **VERIFIED**; evidence `SUB_ABOUT`. Product Lead. - **Edge 45 — `employs` → [[wiki/Angel Bravo|Angel Bravo]]** — **VERIFIED**; evidence `SUB_ABOUT`. Hardware Development Lead. - **Edge 47 — `employs` → [[wiki/Rose Monaghan|Rose Monaghan]]** — **VERIFIED**; evidence `SUB_ABOUT`. Senior R&D Director. - **Edge 49 — `employs` → [[wiki/Cyril Eleftheriou|Cyril Eleftheriou]]** — **VERIFIED**; evidence `SUB_ABOUT`. Scientific Strategy and Partnerships Lead. - **Edge 51 — `employs` → [[wiki/Parminder Mankoo|Parminder Mankoo]]** — **VERIFIED**; evidence `SUB_ABOUT`. Head of AI; pharma/biotech computational biology/chemistry bridge. - **Edge 52 — `employs` → [[wiki/Anthony Di Pasqua|Anthony Di Pasqua]]** — **VERIFIED**; evidence `SUB_ABOUT`. Acting Director R&D Execution; pharmaceutical sciences/nanomaterials bridge. - **Edge 53 — `employs` → [[wiki/Jenny Shao|Jenny Shao]]** — **VERIFIED**; evidence `SUB_ABOUT`. Nanoparticle chemistry. - **Edge 54 — `employs` → [[wiki/Emily Zheng|Emily Zheng]]** — **VERIFIED**; evidence `SUB_ABOUT`. Nanoparticle chemistry, diagnostics, drug delivery. - **Edge 55 — `employs` → [[wiki/Zoë Tosi|Zoë Tosi]]** — **VERIFIED**; evidence `SUB_ABOUT`. Computational neuroscience, ML for biosignals. - **Edge 56 — `employs` → [[wiki/Lucia Rodriguez|Lucia Rodriguez]]** — **VERIFIED**; evidence `SUB_ABOUT`. In-vivo neural recordings. - **Edge 57 — `employs` → [[wiki/Jonathan Levi|Jonathan Levi]]** — **VERIFIED**; evidence `SUB_ABOUT`. Translational neuroscience and materials R&D. - **Edge 104 — `research_neighborhood` → independent MENP/MEND neuromodulation literature** — **ANALYTIC**; evidence `SUB_TECH`, `MENP_HAI_2022`, `MEND_ANIKEEVA`, `MENP_INVIVO`. Important prior-art/materials neighborhood; not evidence of collaboration. - **Edge 105 — `commercial_taxonomy` → pharmaceutical/medical nanoparticle goods + wearable devices + medical services + BCI software** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. USPTO-derived trademark filings show unusually broad product/service coverage across nanoparticles, devices, services and SaaS. - **Edge 106 — `trademark_application` → SUBSENSE serial 99130323 — nanoparticle goods** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 107 — `trademark_application` → SUBSENSE serial 99130328 — wearable electronic/BCI devices** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 108 — `trademark_application` → SUBSENSE serial 99130334 — medical devices** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 109 — `trademark_application` → SUBSENSE serial 99130340 — medical services** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 110 — `trademark_application` → SUBSENSE serial 99130344 — BCI SaaS/software** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 111 — `trademark_application` → SUBSENSE serial 99662030 — Class 005 medical nanoparticles** — **VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2026-02-20; explicit pharmaceutical/medical-use classification strengthens pharmacology adjacency. - **Edge 112 — `research_partner` → [[wiki/UCSC Plasmonic Nanoparticle Research|UCSC plasmonic nanoparticle work]]** — **VERIFIED_SECONDARY**; evidence `SUB_INTERVIEW`. Founder interview explicitly describes UCSC as plasmonic-particle collaborator. - **Edge 113 — `research_partner` → [[wiki/ETH Zürich Magnetoelectric Nanoparticle Research|ETH Zürich magnetoelectric nanoparticle work]]** — **VERIFIED_SECONDARY**; evidence `SUB_INTERVIEW`. Founder interview explicitly describes ETH Zürich as MENP collaborator. - **Edge 144 — `technical_overlay` → DARPA N3 modality search space** — **STRONG_TECHNICAL_CONVERGENCE**; evidence `SUB_TECH`, `DARPA_N3`. Subsense combines optical NIR readout and magnetic nanoparticle write mechanisms that sit squarely inside N3’s optics/electromagnetics/nanotransducer design space; this is not evidence Subsense was an N3 performer. - **Edge 145 — `technical_overlay` → [[wiki/MOANA|MOANA]]** — **STRONG_TECHNICAL_CONVERGENCE**; evidence `SUB_TECH`, `RICE_MOANA`. Both combine optical readout concepts with magnetic nanoparticle-mediated intervention; no public corporate/IP lineage established here. #### Incoming typed edges - **Edge 192 — [[wiki/Motif Neurotech|Motif Neurotech]] `technical_comparison` → this entry** — **ANALYTIC**; evidence `MOTIF_2024`, `SUB_TECH`. Both exploit magnetoelectric physics in neurotechnology, but Motif uses millimeter-scale implanted wireless power/stimulation while Subsense uses nanoparticle-scale distributed transduction. - **Edge 223 — [[wiki/Merge Labs|Merge Labs]] `technical_overlay` → this entry** — **STRONG_TECHNICAL_CONVERGENCE**; evidence `MERGE_OPENAI`, `SUB_TECH`. Both seek high-bandwidth, less-invasive molecular/material-mediated interfaces; transduction differs: ultrasound/biology emphasis versus plasmonic+MENP nanoparticle bioplatform. - **Edge 278 — [[wiki/Blackrock Neurotech|Blackrock Neurotech]] `personnel_line_to` → this entry** — **VERIFIED**; evidence `SUB_ABOUT`. Lindsey Jardine formerly led clinical/regulatory work at Blackrock and now advises Subsense. - **Edge 280 — [[wiki/Blackrock Neurotech|Blackrock Neurotech]] `technological_contrast` → this entry** — **ANALYTIC**; evidence `BLACKROCK_UTAH`, `SUB_TECH`. Penetrating silicon electrodes versus distributed functional nanoparticles + external wearable transceiver; useful comparison axis, not a business relationship. - **Edge 309 — [[wiki/Science Corporation|Science Corporation]] `personnel_line_to` → this entry** — **VERIFIED**; evidence `SUB_ABOUT`. Angel Bravo moved from Science Corp experience into Subsense hardware leadership. - **Edge 408 — [[wiki/Plasmonics|plasmonics]] `bridge_entities` → this entry** — **ANALYTIC**; evidence `SUB_ABOUT`, `SUB_ROUNDTABLE`, `SUB_TECH`. Create a plasmonics-for-neurotechnology entry with separate evidence for each person’s work; do not infer shared IP. - **Edge 409 — [[wiki/Nanoparticle Neural Interface|nanoparticle neural interfaces]] `bridge_entities` → this entry** — **ANALYTIC**; evidence `SUB_TECH`, `MENP_2026`, `DARPA_N3`, `RICE_MOANA`. High-priority related-entry cluster. - **Edge 410 — [[wiki/Less-Invasive Brain-Computer Interface|less-invasive BCI]] `bridge_entities` → this entry** — **ANALYTIC**; evidence `SYNCHRON_TECH`, `SUB_TECH`, `MERGE_OPENAI`, `PRECISION_VISION`. Different access geometries solving common surgery/bandwidth trade-space. - **Edge 414 — [[wiki/Lorimer Ventures|Lorimer Ventures]] `formal_relationship_to` → this entry** — **UNRESOLVED — DO NOT PROMOTE**; evidence `LORIMER_HOME`, `LORIMER_PORTFOLIO`, `LORIMER_THESIS`. No public Lorimer portfolio, thesis, or press evidence located in this research pass. Do not encode an investment/partnership edge without new primary evidence.   #### Consciousness mapping and transfer graph patch — 2026-09-10 **Resolved aliases:** `Subsense` **Collections:** [[collections/Neurotech|Neurotech]] · [[collections/Consciousness Continuity|Consciousness Continuity]] **Relationship source:** [[research/Consciousness Mapping and Transfer Ecosystem Relationship Graph - 2026-09-10|Consciousness Mapping and Transfer Ecosystem Relationship Graph — 2026-09-10]] **Related source articles:** [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] · [[articles/The Architecture of Continuity and Emerging Neuroinformatics Standards|The Architecture of Continuity and Emerging Neuroinformatics Standards]] · [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] · [[articles/The Organic-Synthetic Brain Atlas|The Organic-Synthetic Brain Atlas]] #### Outgoing typed edges - **Edge 7 — `co_founded_by` → [[wiki/Tetiana Aleksandrova|Tetiana Aleksandrova]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Current official team page. - **Edge 8 — `co_founded_by` → [[wiki/Scott Meek|Scott Meek]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Current official team page identifies Head of R&D & Co-Founder. - **Edge 9 — `co_founded_by` → [[wiki/Artem Sokolov|Artem Sokolov]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `GOLDEN_FALCON`. Public founder/funding materials identify Sokolov as co-founder; current Subsense team page foregrounds other founders, so preserve source/date context. - **Edge 10 — `funded_by` → [[wiki/Golden Falcon Capital|Golden Falcon Capital]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_HOME`, `AXIOS_SUB`, `GOLDEN_FALCON`. $17M seed plus $10M extension; Subsense reports $27M total seed financing. - **Edge 12 — `research_partner` → [[wiki/University of California, Santa Cruz|University of California, Santa Cruz]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_HOME`. Partnership stated in company/founder funding materials; connect to NanoEngineering Lab through Ali Yanik. - **Edge 13 — `research_partner` → [[wiki/ETH Zürich|ETH Zürich]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_HOME`. Partnership stated in company/founder funding materials. - **Edge 14 — `platform_contains` → [[wiki/plasmonic nanoparticles|plasmonic nanoparticles]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_TECH`. Optical neural readout via differential NIR scattering in local electric fields. - **Edge 15 — `platform_contains` → [[wiki/magnetoelectric nanoparticles (MENPs)|magnetoelectric nanoparticles (MENPs)]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_TECH`. Targeted neuromodulation by conversion of applied magnetic fields to local electric effects. - **Edge 16 — `platform_contains` → [[wiki/wearable wireless device|wearable wireless device]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_TECH`. External control/readout layer of modular bioplatform. - **Edge 17 — `uses_delivery_route` → intranasal nanoparticle administration** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_HOME`. Company describes non-surgical brain access through intranasal administration. - **Edge 18 — `uses_localization_strategy` → controlled nanoparticle navigation to brain regions** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_HOME`. Company describes targeted localization. - **Edge 19 — `uses_readout_modality` → near-infrared optical scattering** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_TECH`. Plasmonic neural readout. - **Edge 20 — `uses_write_modality` → magnetoelectric neuromodulation** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_TECH`. MENP stimulation. - **Edge 21 — `initial_indication` → [[wiki/Parkinson's Disease|Parkinson’s disease]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_HOME`. Company medical-impact horizon. - **Edge 22 — `initial_indication` → [[wiki/Drug-Resistant Epilepsy|drug-resistant epilepsy]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_HOME`. Company medical-impact horizon. - **Edge 23 — `regulatory_status` → early FDA engagement; no marketing authorization** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_HOME`, `SUB_NEWS`. Do not imply FDA clearance or approval. - **Edge 24 — `advisor` → [[wiki/Ray Kurzweil|Ray Kurzweil]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`, `SUB_NEWS`. Product/vision or scientific-advisor role is current as of 2026-09-09. - **Edge 26 — `advisor` → [[wiki/Naomi J. Halas|Naomi J. Halas]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`, `SUB_ROUNDTABLE`. Plasmonics/nanophotonics bridge. - **Edge 28 — `collaborator` → [[wiki/Ali A. Yanik|Ali A. Yanik]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Director of UCSC NanoEngineering Lab. - **Edge 30 — `advisor` → [[wiki/Sergey Stavisky|Sergey Stavisky]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Speech/language neuroprosthetics bridge. - **Edge 32 — `advisor` → [[wiki/David Eagleman|David Eagleman]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Sensory substitution / neuroplasticity bridge. - **Edge 35 — `regulatory_advisor` → [[wiki/Lindsey Jardine|Lindsey Jardine]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Regulatory transfer from implanted BCI sector. - **Edge 37 — `advisor` → [[wiki/Ajeet Kaushik|Ajeet Kaushik]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. NanoBioTech and drug-delivery/theranostics adjacency. - **Edge 38 — `advisor` → [[wiki/John-Clark Levin|John-Clark Levin]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`, `SUB_ROUNDTABLE`. AI/product strategy bridge to Kurzweil Technologies. - **Edge 40 — `roundtable_participant` → [[wiki/Jennifer Dionne|Jennifer Dionne]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ROUNDTABLE`. Stanford nanophotonics; nanoscale biological observation/control. - **Edge 41 — `roundtable_participant` → [[wiki/Andrew Jackson|Andrew Jackson]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ROUNDTABLE`. Newcastle neural interfaces/brain-machine systems. - **Edge 42 — `roundtable_participant` → [[wiki/Corey Keller|Corey Keller]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ROUNDTABLE`. Stanford neurostimulation and circuit mapping. - **Edge 43 — `employs` → [[wiki/Ranya Belmaachi|Ranya Belmaachi]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Product Lead. - **Edge 45 — `employs` → [[wiki/Angel Bravo|Angel Bravo]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Hardware Development Lead. - **Edge 47 — `employs` → [[wiki/Rose Monaghan|Rose Monaghan]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Senior R&D Director. - **Edge 49 — `employs` → [[wiki/Cyril Eleftheriou|Cyril Eleftheriou]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Scientific Strategy and Partnerships Lead. - **Edge 51 — `employs` → [[wiki/Parminder Mankoo|Parminder Mankoo]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Head of AI; pharma/biotech computational biology/chemistry bridge. - **Edge 52 — `employs` → [[wiki/Anthony Di Pasqua|Anthony Di Pasqua]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Acting Director R&D Execution; pharmaceutical sciences/nanomaterials bridge. - **Edge 53 — `employs` → [[wiki/Jenny Shao|Jenny Shao]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Nanoparticle chemistry. - **Edge 54 — `employs` → [[wiki/Emily Zheng|Emily Zheng]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Nanoparticle chemistry, diagnostics, drug delivery. - **Edge 55 — `employs` → [[wiki/Zoë Tosi|Zoë Tosi]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Computational neuroscience, ML for biosignals. - **Edge 56 — `employs` → [[wiki/Lucia Rodriguez|Lucia Rodriguez]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. In-vivo neural recordings. - **Edge 57 — `employs` → [[wiki/Jonathan Levi|Jonathan Levi]]** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Translational neuroscience and materials R&D. - **Edge 104 — `research_neighborhood` → [[wiki/independent MENP and MEND neuromodulation literature|independent MENP/MEND neuromodulation literature]]** — **PRIOR_NEUROTECH_ANALYTIC**; evidence `SUB_TECH`, `MENP_HAI_2022`, `MEND_ANIKEEVA`, `MENP_INVIVO`. Important prior-art/materials neighborhood; not evidence of collaboration. - **Edge 105 — `commercial_taxonomy` → pharmaceutical/medical nanoparticle goods + wearable devices + medical services + BCI software** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. USPTO-derived trademark filings show unusually broad product/service coverage across nanoparticles, devices, services and SaaS. - **Edge 106 — `trademark_application` → [[wiki/SUBSENSE serial 99130323 — nanoparticle goods|SUBSENSE serial 99130323 — nanoparticle goods]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 107 — `trademark_application` → [[wiki/SUBSENSE serial 99130328 — wearable electronic and BCI devices|SUBSENSE serial 99130328 — wearable electronic/BCI devices]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 108 — `trademark_application` → [[wiki/SUBSENSE serial 99130334 — medical devices|SUBSENSE serial 99130334 — medical devices]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 109 — `trademark_application` → [[wiki/SUBSENSE serial 99130340 — medical services|SUBSENSE serial 99130340 — medical services]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 110 — `trademark_application` → [[wiki/SUBSENSE serial 99130344 — BCI SaaS and software|SUBSENSE serial 99130344 — BCI SaaS/software]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2025-04-10. - **Edge 111 — `trademark_application` → [[wiki/SUBSENSE serial 99662030 — Class 005 medical nanoparticles|SUBSENSE serial 99662030 — Class 005 medical nanoparticles]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_TRADEMARKS`. Filed 2026-02-20; explicit pharmaceutical/medical-use classification strengthens pharmacology adjacency. - **Edge 112 — `research_partner` → [[wiki/UCSC plasmonic nanoparticle work|UCSC plasmonic nanoparticle work]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_INTERVIEW`. Founder interview explicitly describes UCSC as plasmonic-particle collaborator. - **Edge 113 — `research_partner` → [[wiki/ETH Zürich magnetoelectric nanoparticle work|ETH Zürich magnetoelectric nanoparticle work]]** — **PRIOR_NEUROTECH_VERIFIED_SECONDARY**; evidence `SUB_INTERVIEW`. Founder interview explicitly describes ETH Zürich as MENP collaborator. - **Edge 144 — `technical_overlay` → [[wiki/DARPA N3 modality search space|DARPA N3 modality search space]]** — **PRIOR_NEUROTECH_STRONG_TECHNICAL_CONVERGENCE**; evidence `SUB_TECH`, `DARPA_N3`. Subsense combines optical NIR readout and magnetic nanoparticle write mechanisms that sit squarely inside N3’s optics/electromagnetics/nanotransducer design space; this is not evidence Subsense was an N3 performer. - **Edge 145 — `technical_overlay` → [[wiki/MOANA|MOANA]]** — **PRIOR_NEUROTECH_STRONG_TECHNICAL_CONVERGENCE**; evidence `SUB_TECH`, `RICE_MOANA`. Both combine optical readout concepts with magnetic nanoparticle-mediated intervention; no public corporate/IP lineage established here. - **Edge 692 — `announced` → Ray Kurzweil as Product and Vision Advisor** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_NEWS`. Sep 9 2026. - **Edge 700 — `current_cofounder_profile_names` → Tetiana Aleksandrova and Scott Meek** — **SOURCE_VERSION_CONFLICT**; evidence `SUB_CURRENT_ABOUT`. Current About page should be reconciled against older launch materials naming Artem Sokolov as co-founder. #### Incoming typed edges - **Edge 192 — [[wiki/Motif Neurotech|Motif Neurotech]] `technical_comparison` → this entry** — **PRIOR_NEUROTECH_ANALYTIC**; evidence `MOTIF_2024`, `SUB_TECH`. Both exploit magnetoelectric physics in neurotechnology, but Motif uses millimeter-scale implanted wireless power/stimulation while Subsense uses nanoparticle-scale distributed transduction. - **Edge 223 — [[wiki/Merge Labs|Merge Labs]] `technical_overlay` → this entry** — **PRIOR_NEUROTECH_STRONG_TECHNICAL_CONVERGENCE**; evidence `MERGE_OPENAI`, `SUB_TECH`. Both seek high-bandwidth, less-invasive molecular/material-mediated interfaces; transduction differs: ultrasound/biology emphasis versus plasmonic+MENP nanoparticle bioplatform. - **Edge 278 — [[wiki/Blackrock Neurotech|Blackrock Neurotech]] `personnel_line_to` → this entry** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Lindsey Jardine formerly led clinical/regulatory work at Blackrock and now advises Subsense. - **Edge 280 — [[wiki/Blackrock Neurotech|Blackrock Neurotech]] `technological_contrast` → this entry** — **PRIOR_NEUROTECH_ANALYTIC**; evidence `BLACKROCK_UTAH`, `SUB_TECH`. Penetrating silicon electrodes versus distributed functional nanoparticles + external wearable transceiver; useful comparison axis, not a business relationship. - **Edge 309 — [[wiki/Science Corporation|Science Corporation]] `personnel_line_to` → this entry** — **PRIOR_NEUROTECH_VERIFIED**; evidence `SUB_ABOUT`. Angel Bravo moved from Science Corp experience into Subsense hardware leadership. - **Edge 408 — [[wiki/Plasmonics|plasmonics]] `bridge_entities` → this entry** — **PRIOR_NEUROTECH_ANALYTIC**; evidence `SUB_ABOUT`, `SUB_ROUNDTABLE`, `SUB_TECH`. Create a plasmonics-for-neurotechnology entry with separate evidence for each person’s work; do not infer shared IP. - **Edge 414 — [[wiki/Lorimer Ventures|Lorimer Ventures]] `formal_relationship_to` → this entry** — **PRIOR_NEUROTECH_UNRESOLVED**; evidence `LORIMER_HOME`, `LORIMER_PORTFOLIO`, `LORIMER_THESIS`. No public Lorimer portfolio, thesis, or press evidence located in this research pass. Do not encode an investment/partnership edge without new primary evidence. - **Edge 691 — [[wiki/Ray Kurzweil|Ray Kurzweil]] `advisor_to` → this entry** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_ABOUT`, `SUB_CURRENT_NEWS`. The current Subsense About page lists him as a product advisor, and the September 9, 2026 news announcement names him Product and Vision Advisor. - **Edge 695 — [[wiki/Naomi J. Halas|Naomi J. Halas]] `advisor_to` → this entry** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_ABOUT`. Rice University plasmonics/gold nanoshells bridge. - **Edge 696 — [[wiki/Ali A. Yanik|Ali A. Yanik]] `collaborator_with` → this entry** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_ABOUT`. UCSC NanoEngineering Lab. - **Edge 697 — [[wiki/Sergey Stavisky|Sergey Stavisky]] `advisor_to` → this entry** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_ABOUT`. UC Davis Neuroprosthetics Lab / speech-language restoration. - **Edge 698 — [[wiki/David Eagleman|David Eagleman]] `advisor_to` → this entry** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_ABOUT`. Sensory substitution / neuroscience bridge. - **Edge 699 — [[wiki/Ajeet Kaushik|Ajeet Kaushik]] `advisor_to` → this entry** — **VERIFIED_CURRENT**; evidence `SUB_CURRENT_ABOUT`. Nanobiotechnology bridge.